Tuberculosis (TB) continues to be a global health threat, particularly affecting vulnerable populations, including children. This webinar aims to explore critical aspects of TB vaccine development, encompassing sample collection, including the application of microsampling, the definition and prioritization of biomarkers, functional characterization through flow cytometry, data analysis pipelines and the integration of new and potential future technologies.
Sample Collection:
Proper sample collection is crucial for successful clinical trials. The featured speakers will discuss how sample type is determined by analyte stability, downstream analysis and participant volume restrictions. Microsampling techniques will be highlighted as an innovative approach to support clinical pediatric studies, which minimize sample volumes and invasiveness while maintaining the integrity of the collected samples. The speakers will share insights on how microsampling can facilitate pediatric studies, contributing to improved TB vaccine evaluation and monitoring.
Biomarkers:
Defining and prioritizing biomarkers for TB vaccination is essential for understanding immune responses and identifying correlates of protection. This webinar will delve into the current research landscape, discussing challenges and opportunities in identifying biomarkers that can guide the development and evaluation of effective TB vaccines, with particular consideration for the pediatric population.
Read more... Functional characterization through flow cytometry offers valuable insights into immune responses elicited by TB vaccines. Explore cutting-edge methodologies and case studies to shed light on the use of flow cytometry to comprehensively analyze immune cell subsets, cytokine production and immune activation markers, aiding in the understanding of vaccine-induced immune responses and their implications for protection against TB. Data Analysis: Data analysis pipelines are crucial for extracting meaningful information from complex datasets generated in TB vaccination research. The speakers will provide an overview of various computational tools and approaches used in the analysis of immunological data, enabling attendees to navigate the challenges associated with data processing, integration and interpretation. Read Less...
New and Potential Future Technologies:
The webinar will explore new and future technologies that have the potential to advance TB vaccine development. From novel vaccine platforms to innovative diagnostic tools, attendees will gain insights into emerging technologies that hold promise for the prevention, diagnosis and treatment of TB, with a specific focus on pediatric populations.
Register for this webinar on accelerating the progress in TB vaccine development with insights from microsampling, biomarkers and data analysis.
Speakers
Professor Thomas Scriba MSc (Stell), DPhil (Oxon), Deputy Director (Immunology), South African Tuberculosis Vaccine Initiative (SATVI)
Thomas Scriba is the Deputy Director (Immunology) of the South African Tuberculosis Vaccine Initiative (SATVI) and Member of the Institute of Infectious Disease and Molecular Medicine (IDM), Division of Immunology, Department of Pathology, Faculty of Health Sciences, University of Cape Town. SATVI’s mission is the development of new and effective prevention strategies against tuberculosis (TB), including vaccination and biomarker-targeted treatment approaches. They are testing multiple new vaccine candidates in clinical trials; and are involved with projects to address critical clinical, epidemiological, immunological and human genetic questions in TB pathogenesis and vaccine development. Tom’s particular interests focus on understanding the immunopathology of Mycobacterium tuberculosis infection and TB disease developing correlates of risk and immunological correlates of protection against TB.
Message Presenter
Nicholas Woudberg, PhD, Head of Scientific Strategies, Synexa Life Sciences
Nicholas Woudberg is a medical scientist with a PhD in medicine and more than five years of experience in both academic and industry research, specializing in soluble biomarkers.
He joined Synexa in 2019, starting in the soluble biomarkers lab. In 2021, Nicholas transitioned into a more commercial role, helping clients answer their most pressing bioanalytical questions. Heading up the Scientific Strategies Team, he draws upon his extensive scientific knowledge to help clients develop biomarker strategies that are both effective and impactful.
Message PresenterWho Should Attend?
- Pharmaceutical and Biotechnology Industry Representatives: Representatives from pharmaceutical and biotechnology companies involved in TB vaccine research and development
- Researchers and Scientists: Scientists and researchers actively involved in TB vaccination research, including those investigating biomarkers, flow cytometry, microsampling, data analysis and new technologies
- Immunologists and Virologists: Immunologists and virologists interested in understanding immune responses and immune cell functionality induced by TB vaccines
Relevant Job Roles
- Medical Directors/Senior Medical Directors
- Clinical/Translational Biomarker Leads
- Clinical Development Directors
- Clinical Trial Managers
- Purchasing Managers
- Project Directors/Managers
- Immunologists
- Virologists
Relevant Job Areas
- Clinical Research
- Clinical Operations
- Clinical Outsourcing
- Project Management
What You Will Learn
Attendees will:
- Explore the advantages and challenges of microsampling techniques in supporting clinical pediatric studies, minimising invasiveness while maintaining sample integrity for improved TB vaccine evaluation and monitoring
- Gain insights into the process of defining and prioritising biomarkers for TB vaccination, enabling the identification of reliable indicators for vaccine response prediction and development of tailored pediatric vaccines
- Acquire knowledge of data analysis pipelines and computational tools used in TB vaccination research, facilitating robust analysis of immunological data and extraction of meaningful insights for vaccine development
Xtalks Partner
Synexa
Synexa is an industry leading biomarker and large molecule bioanalytical research service provider. Our core expertise is in the understanding of immune system mediated diseases and therapeutic modulation of the immune system.
For nearly 20 years we have supported our partners across the globe to achieve their clinical milestones. As a science driven organization, we deliver bespoke bioanalytical solutions to meet each of our client’s specific needs. Our purpose-built laboratories located in London, Berlin, Cape Town and Rockville, Maryland (USA) have been designed to meet the rapidly evolving complexity of drug development pipelines.
Related Webinars
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account